Literature DB >> 17529993

SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery.

Matthew J Gamble1, Robert P Fisher.   

Abstract

The histone chaperone SET is required for transcription of chromatin templates by RNA polymerase Pol II (Pol II) in vitro. Here we uncover a positive role for SET in dislodging DEK and PARP1, which restrict access to chromatin in the absence of SET and the PARP1 substrate NAD(+). SET binds chromatin, dissociating DEK and PARP1 to allow transcription in the absence of NAD(+). In the absence of SET, depletion of DEK restores chromatin accessibility to endonuclease but does not permit Mediator recruitment or transcription. In the presence of NAD(+), PARP1 poly(ADP-ribosyl)ates and evicts DEK (and itself) from chromatin to permit Mediator loading and transcription independent of SET. An artificial DEK variant resistant to SET and PARP1 represses transcription, indicating a requirement for DEK removal. Therefore, SET, DEK and PARP1 constitute a network governing access to chromatin by the transcription machinery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17529993     DOI: 10.1038/nsmb1248

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  56 in total

Review 1.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  The N-terminal Set-β Protein Isoform Induces Neuronal Death.

Authors:  Ephraim F Trakhtenberg; Melina I Morkin; Karan H Patel; Stephanie G Fernandez; Alan Sang; Peter Shaw; Xiongfei Liu; Yan Wang; Gregory M Mlacker; Han Gao; Dmitry Velmeshev; Susan M Dombrowski; Michael P Vitek; Jeffrey L Goldberg
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157

Review 3.  Genetic and epigenetic underpinnings of sex differences in the brain and in neurological and psychiatric disease susceptibility.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  The nuclear DEK interactome supports multi-functionality.

Authors:  Eric A Smith; Eric F Krumpelbeck; Anil G Jegga; Malte Prell; Marie M Matrka; Ferdinand Kappes; Kenneth D Greis; Abdullah M Ali; Amom R Meetei; Susanne I Wells
Journal:  Proteins       Date:  2017-11-11

5.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

Review 6.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

7.  Use of biotinylated plasmid DNA as a surrogate for HSV DNA to identify proteins that repress or activate viral gene expression.

Authors:  Stephen Mallon; Bassam T Wakim; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-05       Impact factor: 11.205

Review 8.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 9.  Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.

Authors:  W Lee Kraus
Journal:  Curr Opin Cell Biol       Date:  2008-04-29       Impact factor: 8.382

10.  PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Authors:  Vimal Selvaraj; Mangala M Soundarapandian; Olga Chechneva; Ambrose J Williams; Maxim K Sidorov; Athena M Soulika; David E Pleasure; Wenbin Deng
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.